Literature DB >> 34174296

Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease.

Kathleen M Buchheit1, Tanya M Laidlaw2, Joshua M Levy3.   

Abstract

Entities:  

Keywords:  Aspirin-exacerbated respiratory disease; IL-4Rα; IL-5Rα; IgE; benralizumab; dupilumab; mepolizumab; nasal polyp; omalizumab; respiratory biologic

Mesh：

Substances：

Year:  2021        PMID： 34174296      PMCID： PMC9022378          DOI： 10.1016/j.jaci.2021.06.019

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   14.290


× No keyword cloud information.
  10 in total

1.  Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD.

Authors:  Tanya M Laidlaw; Joaquim Mullol; Chunpeng Fan; Donghui Zhang; Nikhil Amin; Asif Khan; Jingdong Chao; Leda P Mannent
Journal:  J Allergy Clin Immunol Pract       Date:  2019-04-04

Review 2.  Aspirin-Exacerbated Respiratory Disease.

Authors:  Andrew A White; Donald D Stevenson
Journal:  N Engl J Med       Date:  2018-09-13       Impact factor: 91.245

3.  Omalizumab reduces cysteinyl leukotriene and 9α,11β-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease.

Authors:  Hiroaki Hayashi; Chihiro Mitsui; Eiji Nakatani; Yuma Fukutomi; Keiichi Kajiwara; Kentaro Watai; Kiyoshi Sekiya; Takahiro Tsuburai; Kazuo Akiyama; Yoshinori Hasegawa; Masami Taniguchi
Journal:  J Allergy Clin Immunol       Date:  2015-11-11       Impact factor: 10.793

4.  Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size.

Authors:  Tanya M Laidlaw; Calman Prussin; Reynold A Panettieri; Stella Lee; Berrylin J Ferguson; Nithin D Adappa; Andrew P Lane; Marina L Palumbo; Mary Sullivan; Don Archibald; Steven I Dworetzky; Gregory T Hebrank; Michael E Bozik
Journal:  Laryngoscope       Date:  2018-10-04       Impact factor: 3.325

5.  IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease.

Authors:  Kathleen M Buchheit; Daniel F Dwyer; Jose Ordovas-Montanes; Howard R Katz; Erin Lewis; Marko Vukovic; Juying Lai; Lora G Bankova; Neil Bhattacharyya; Alex K Shalek; Nora A Barrett; Joshua A Boyce; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol       Date:  2020-03-19       Impact factor: 10.793

6.  Inflammatory heterogeneity in aspirin-exacerbated respiratory disease.

Authors:  William C Scott; Katherine N Cahill; Ginger L Milne; Ping Li; Quanhu Sheng; Li Ching Huang; Spencer Dennis; Jacob Snyder; Ashley M Bauer; Rakesh K Chandra; Naweed I Chowdhury; Justin H Turner
Journal:  J Allergy Clin Immunol       Date:  2020-11-12       Impact factor: 10.793

7.  Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Joseph K Han; Claus Bachert; Wytske Fokkens; Martin Desrosiers; Martin Wagenmann; Stella E Lee; Steven G Smith; Neil Martin; Bhabita Mayer; Steven W Yancey; Ana R Sousa; Robert Chan; Claire Hopkins
Journal:  Lancet Respir Med       Date:  2021-04-16       Impact factor: 30.700

8.  Efficacy of dupilumab in patients with aspirin-exacerbated respiratory disease and previous inadequate response to anti-IL-5 or anti-IL-5Rα in a real-world setting.

Authors:  Nicole Bavaro; Deborah Gakpo; Anisha Mittal; Jillian C Bensko; Tanya M Laidlaw; Kathleen M Buchheit
Journal:  J Allergy Clin Immunol Pract       Date:  2021-02-22

9.  Allergic inflammatory memory in human respiratory epithelial progenitor cells.

Authors:  Jose Ordovas-Montanes; Daniel F Dwyer; Sarah K Nyquist; Kathleen M Buchheit; Marko Vukovic; Chaarushena Deb; Marc H Wadsworth; Travis K Hughes; Samuel W Kazer; Eri Yoshimoto; Katherine N Cahill; Neil Bhattacharyya; Howard R Katz; Bonnie Berger; Tanya M Laidlaw; Joshua A Boyce; Nora A Barrett; Alex K Shalek
Journal:  Nature       Date:  2018-08-22       Impact factor: 49.962

10.  Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease.

Authors:  Kathleen M Buchheit; Erin Lewis; Deborah Gakpo; Jonathan Hacker; Aaqib Sohail; Faith Taliaferro; Evans Berreondo Giron; Chelsea Asare; Marko Vukovic; Jillian C Bensko; Daniel F Dwyer; Alex K Shalek; Jose Ordovas-Montanes; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol       Date:  2021-06-16       Impact factor: 14.290
  10 in total
  2 in total

1.  Dupilumab as an adjunct to surgery in patients with aspirin-exacerbated respiratory disease.

Authors:  Pooja Patel; Jillian C Bensko; Neil Bhattacharyya; Tanya M Laidlaw; Kathleen M Buchheit
Journal:  Ann Allergy Asthma Immunol       Date:  2021-12-01       Impact factor: 6.347

2.  Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: Efficacy, tolerability, and patient experience.

Authors:  Jyotsna Mullur; Camille M Steger; Deborah Gakpo; Jillian C Bensko; Rie Maurer; Tanya M Laidlaw; Kathleen M Buchheit
Journal:  Ann Allergy Asthma Immunol       Date:  2022-02-05       Impact factor: 6.248
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.